PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32932915-9 2020 In addition, mRNA levels of pro-inflammatory cytokines, including TNF-alpha, IL-1beta, and IFN-beta, were significantly decreased by combined ginsenoside treatment. Ginsenosides 142-153 tumor necrosis factor Mus musculus 66-75 34034706-7 2021 LPS-induced RAW264.7 cells and TNF-alpha-induced HUVEC cells were cultured with MTX, DMSO and six ginsenosides, respectively. Ginsenosides 98-110 tumor necrosis factor Mus musculus 31-40 26693244-0 2015 Synergistic Use of Geniposide and Ginsenoside Rg1 Balance Microglial TNF-alpha and TGF-beta1 following Oxygen-Glucose Deprivation In Vitro: A Genome-Wide Survey. Ginsenosides 34-45 tumor necrosis factor Mus musculus 69-78 30826410-5 2019 Additionally, ginsenoside Rk3 significantly reduced the expression of inflammatory cytokines, such as NF-kappaB, TNF-alpha, IL-6, and IL-1beta in the mice. Ginsenosides 14-25 tumor necrosis factor Mus musculus 113-122 29103460-8 2017 Ginsenoside Rk1 inhibited lipopolysaccharide-induced expression of nitric oxide (NO), interleukin (IL)-6, IL-1beta, tumor necrosis factor (TNF)-alpha, and monocyte chemotactic protein (MCP)-1. Ginsenosides 0-11 tumor necrosis factor Mus musculus 116-149 32933639-11 2020 Compared with the low-dose ginsenoside Rb1 group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-alpha, IL-6, and IL-1beta (P<0.05); the high-dose ginsenoside Rb1 group had significant increases in the expression levels of P-PI3K/PI3K and P-AKT/AKT (P<0.05). Ginsenosides 27-38 tumor necrosis factor Mus musculus 152-161 32933639-11 2020 Compared with the low-dose ginsenoside Rb1 group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-alpha, IL-6, and IL-1beta (P<0.05); the high-dose ginsenoside Rb1 group had significant increases in the expression levels of P-PI3K/PI3K and P-AKT/AKT (P<0.05). Ginsenosides 86-97 tumor necrosis factor Mus musculus 152-161 32020864-0 2020 Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model. Ginsenosides 0-11 tumor necrosis factor Mus musculus 62-71 26693244-2 2015 The aim of this study was to reveal the synergistic effect of geniposide and ginsenoside Rg1 based on tumor necrosis factor- (TNF-) alpha and transforming growth factor- (TGF-) beta1 balance of microglia. Ginsenosides 77-88 tumor necrosis factor Mus musculus 102-137 26693244-5 2015 The results showed that integrated use of geniposide and ginsenoside Rg1 significantly inhibited NO level and protected cell viability, improved the content and expression of TGF-beta1, and reduced the content and expression of TNF-alpha. Ginsenosides 57-68 tumor necrosis factor Mus musculus 228-237 24137309-11 2013 Ginsenoside Rg1 also demonstrated a potential regulatory effect on the UVB-induced local expression of the mRNA of the cytokines IFN-gamma, IL-10 and TNF-alpha, which may be important in its immunoregulatory and inflammatory mechanisms. Ginsenosides 0-11 tumor necrosis factor Mus musculus 150-159 25431611-3 2014 Ginsenoside Rg1, the primary active ingredient in Panax ginseng (also termed Asian or Korean ginseng), has been reported to inhibit TNF-alpha production and has been shown to significantly attenuate liver fibrosis development. Ginsenosides 0-11 tumor necrosis factor Mus musculus 132-141 25431611-5 2014 We found that ginsenoside Rg1 significantly reduces liver damage in a murine ALF model through inhibiting TNF-alpha-induced, caspase-dependent hepatocellular apoptosis. Ginsenosides 14-25 tumor necrosis factor Mus musculus 106-115 22849695-9 2012 Orally administered ginsenoside Re significantly inhibited the expression of IL-1beta and TNF-alpha on LPS-induced systemic inflammation and TNBS-induced colitis in mice. Ginsenosides 20-31 tumor necrosis factor Mus musculus 90-99 23545455-0 2013 Ginsenoside Re reduces insulin resistance through activation of PPAR-gamma pathway and inhibition of TNF-alpha production. Ginsenosides 0-11 tumor necrosis factor Mus musculus 101-110 23545455-16 2013 CONCLUSIONS: Ginsenoside Re exhibited the action of reducing insulin resistance through activation of PPAR-gamma pathway by directly increasing the expressions of PPAR-gamma2 and its responsive genes, adiponectin, IRS-1, ap2, inhibiting TNF-alpha production and facilitating the translocation of GLUT4 to promote glucose uptake and disposal in 3T3-L1 adipocytes. Ginsenosides 13-24 tumor necrosis factor Mus musculus 237-246 22849695-5 2012 Ginsenoside Re inhibited IKK-beta phosphorylation and NF-kappaB activation, as well as the expression of proinflammatory cytokines, TNF-alpha and IL-1beta, in LPS-stimulated peritoneal macrophages, but it did not inhibit them in TNF-alpha- or PG-stimulated peritoneal macrophages. Ginsenosides 0-11 tumor necrosis factor Mus musculus 132-141 18409051-4 2008 The ginsenosides, Rb1, Rb2, Rc, Rd, Re, Rf and Rg1, significantly attenuated the nociceptive behavior induced by TNF-alpha, IL-1 beta, and IFN-gamma injection, but ginsenoside-Rg3 did not. Ginsenosides 4-16 tumor necrosis factor Mus musculus 113-122 22849695-5 2012 Ginsenoside Re inhibited IKK-beta phosphorylation and NF-kappaB activation, as well as the expression of proinflammatory cytokines, TNF-alpha and IL-1beta, in LPS-stimulated peritoneal macrophages, but it did not inhibit them in TNF-alpha- or PG-stimulated peritoneal macrophages. Ginsenosides 0-11 tumor necrosis factor Mus musculus 229-238 22975507-6 2012 Ginsenoside Rg3 at 20 and 30 mg/kg oral doses significantly attenuated up-regulation of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and IL-6 mRNA in brain tissue at 4 h after LPS injection. Ginsenosides 0-11 tumor necrosis factor Mus musculus 88-115 22975507-6 2012 Ginsenoside Rg3 at 20 and 30 mg/kg oral doses significantly attenuated up-regulation of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and IL-6 mRNA in brain tissue at 4 h after LPS injection. Ginsenosides 0-11 tumor necrosis factor Mus musculus 117-126 18409051-4 2008 The ginsenosides, Rb1, Rb2, Rc, Rd, Re, Rf and Rg1, significantly attenuated the nociceptive behavior induced by TNF-alpha, IL-1 beta, and IFN-gamma injection, but ginsenoside-Rg3 did not. Ginsenosides 4-15 tumor necrosis factor Mus musculus 113-122 34671254-10 2021 Moreover, ginsenoside Rk3 slowed or halted increases in malondialdehyde, matrix metalloproteinase (MMP)-1, and MMP-3 levels in the blood and levels of interleukin 1, interleukin 6, and tumor necrosis factor alpha in skin tissues. Ginsenosides 10-21 tumor necrosis factor Mus musculus 185-212 16964764-3 2006 These ginsenosides also reduced mRNA expressions of cyclooxygenase-2, interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma. Ginsenosides 6-18 tumor necrosis factor Mus musculus 94-127 16964764-5 2006 These findings suggest that ginsenoside Rh3 metabolized from ginsenoside Rg5 may improve chronic dermatitis or psoriasis by the regulation of IL-1beta and TNF-alpha produced by macrophage cells and of IFN-gamma produced by Th cells. Ginsenosides 28-39 tumor necrosis factor Mus musculus 155-164